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The short-chain fatty acid acetate reduces appetite
via a central homeostatic mechanism
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Increased intake of dietary carbohydrate that is fermented in the colon by the microbiota has
been reported to decrease body weight, although the mechanism remains unclear. Here
we use in vivo 11C-acetate and PET-CT scanning to show that colonic acetate crosses
the blood–brain barrier and is taken up by the brain. Intraperitoneal acetate results in appetite
suppression and hypothalamic neuronal activation patterning. We also show that acetate
administration is associated with activation of acetyl-CoA carboxylase and changes in
the expression profiles of regulatory neuropeptides that favour appetite suppression.
Furthermore, we demonstrate through 13C high-resolution magic-angle-spinning that 13C
acetate from fermentation of 13C-labelled carbohydrate in the colon increases hypothalamic
13C acetate above baseline levels. Hypothalamic 13C acetate regionally increases the
13C labelling of the glutamate–glutamine and GABA neuroglial cycles, with hypothalamic 13C
lactate reaching higher levels than the ‘remaining brain’. These observations suggest that
acetate has a direct role in central appetite regulation.
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O
besity has reached epidemic proportions worldwide, with
incidence rates above 20% in most western countries
now representing a major public health burden1. This
rise in obesity is fuelled by the mismatch between an inherited
genetic predisposition for survival in environments where food
supply is limited and the current obesogenic environment where
reduced physical activity and excess energy intake prevails2.
Modern food processing has resulted in the mass production of
cheap, energy-dense foods that are generally high in refined
sugars and fats but low in fibre3. It has been estimated that the
Palaeolithic diet delivered 4100 g per day of fibre, whereas
current western intakes are only between 10 and 20 g per day4.
Much of the fibre consumed in the Palaeolithic diet, unlike
current fibre intake, would have been highly fermentable. There is
a growing body of evidence that links fermentation of dietary
carbohydrate (including fibre) by the colonic microbiota to
positive effects on metabolism5. Observations by Cani et al.6
demonstrated that rats exposed to a high-fat diet (HFD) with
an increased fermentable carbohydrate (FC) component for
4 weeks had lower dietary energy intake, body weight and
adiposity, suggesting that increased dietary FC leads to
improved appetite and body weight regulation. FCs are thought
to promote the release of the anorectic gut hormones peptide
YY (PYY) and glucagon-like peptide-1 (GLP-1) (ref. 7). However,
FC-associated weight loss in human and rodent models have
failed to consistently show increases in these anorectic
hormones8.
We have recently shown in mice that dietary FC supplementa-
tion is associated with reduced energy intake, body weight,
adiposity and changes in hypothalamic neuronal activation
patterns, all of which were independent of changes in circulating
concentrations of GLP-1 (ref. 9). To better understand the
mechanism behind the anorectic action of FC supplementation,
we investigated the direct effects of the most abundant end
product of colonic FC fermentation, the short-chain fatty acid
(SCFA) acetate, on the control of appetite.
We present herein that acetate derived from the colonic
fermentation of FC acts to directly supress appetite through
central hypothalamic mechanisms involving changes in transcel-
lular neurotransmitter cycles. This, therefore, opens up new
research directions into the promotion of acetate production by
colonic microbiota and therapeutic strategies for the prevention
and treatment of obesity.
Results
The effect of FCs on body weight. We fed C57BL/6 mice with
HFD supplemented with either the FC inulin (HF-I) or the poorly
fermentable fibre cellulose (HF-C). After 8 weeks, mice fed the
HF-I diet gained significantly less weight than those fed
HF-C (Fig. 1a) and consumed significantly less food (Fig. 1b).
SCFA analysis of the colonic content of the former animals
demonstrated a significant increase in total SCFA concentrations
and especially the most abundant SCFA, acetate (Fig. 1c).
Although others have reported that FC supplementation leads to
an increase in the anorectic hormones GLP-1 and PYY6, our
group has recently reported that FC-rich diets increase
manganese-enhanced MRI (MEMRI) signal in the hypo-
thalamus, a proxy of neuronal activation, via a mechanism
that appears to be independent of changes in GLP-1 (ref. 9).
In support of this, infusion of anorectic gut hormones have
previously been shown to suppress hypothalamic MEMRI
signal10, thereby suggesting that any increase in signal seen
following FC supplementation is not PYY or GLP-1 dependent.
We therefore hypothesized that there was a direct effect of
SCFAs on appetite regulation, namely by acetate, given it is
the most abundant SCFA produced in the colon, and that it
partially avoids hepatic clearance to reach micromolar con-
centrations in the peripheral circulation.
The biodistribution of acetate and uptake in the brain. SCFA
have traditionally been thought to be almost entirely metabolized
by colonocytes and the liver11. However, acetate is present in the
peripheral circulation, in human cerebrospinal fluid12 as well as
in the brain where it provides an important energy source for glial
cells13. To our knowledge, there has been no previous publication
investigating acetate as a potential appetite-regulating agent. We
therefore sought to investigate the biodistribution of acetate
administered peripherally or by administering it colonically to
mimic the endogenous production from FC. To do this, we used
in vivo intravenous (i.v.) and colonic infusions of 11C-acetate and
PET-CT in mice. A representative PET-CT image of a fasted
mouse following i.v. 11C-acetate infusion is shown in Fig. 1d. The
liver and heart demonstrated the greatest proportion of initial
11C-acetate dose uptake (Fig. 1f,g), but our data also show that up
to 3% of the initial acetate tracer was taken up by the brain
following i.v. infusions in both the fed and fasted states (Fig. 1e).
Brain uptake following colonic infusion was more gradual, but it
reached an equivalent level after B20min.
Acetate reduces acute food intake. We went on to test whether
acetate was itself an anorectic signal using acute peripheral
administration in C57BL/6 mice. Intraperitoneal (i.p.) injection of
acetate (500mg kg 1) produced an increase in serum acetate
(Fig. 2a), similar to those that have been associated with sup-
pression of free fatty acids14, which was associated with a
significant reduction in acute food intake at both 1 and 2 h post
injection (Fig. 2b). An acetate tolerance test demonstrated that
there was no impact of i.p. acetate at 500mg kg 1 body weight
on blood glucose concentrations (Fig. 2e). Acute behavioural
observations post injection showed that this was also not
associated with aversive behaviour (Fig. 2d). Furthermore, at
60 min post injection, there were no significant differences in
circulating concentrations of plasma PYY and GLP-1 (Fig. 2g,h).
We encapsulated acetate into liposomes15. Using this method of
peripheral administration of liposome-encapsulated acetate over a
4-h period, we did not detect liposomes in the hypothalamus or
changes in food intake (Fig. 2f). We therefore hypothesized that
the anorectic effects of acetate may result from a direct effect on
the central nervous system. We tested this hypothesis by
administering 2.5 mmol of sodium acetate directly into the third
ventricle of intracerebroventricular (i.c.v.) cannulated male
Wistar rats. In accordance with the anorectic effects of
peripherally administered acetate, central administration of
acetate into the third ventricle suppressed food intake primarily
at 1–2 h post injection, resulting in reduced cumulative food
intake at both at 2 and 4 h (Fig. 2c), although this effect was not as
potent as the suppression observed after i.p. administration of
acetate in mice. The short-term suppressions of feeding were as
expected given the rapid hepatic metabolism and short half-life of
acetate.
Acetate induces an anorectic neuropeptide expression profile.
Having confirmed that acetate was an anorectic agent and
was indeed taken up by the brain following colonic or i.v.
administration, we next sought to confirm whether changes in
hypothalamic neuronal activation that we had previously
observed following dietary supplementation of FC9 could be
replicated following an acute administration of acetate. To
achieve this, we again used the in vivo functional imaging
technique MEMRI9,10,16. The regions of interest examined were
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as shown in Fig. 3a. Mice given an i.p. injection of an anorectic
dose of acetate had a significant increase in signal intensity in the
arcuate nucleus (ARC), indicative of increased neuronal
activation, whereas no significant differences were observed in
the ventral medial hypothalamus (VMH), the paraventricular
nucleus (PVN) (Fig. 3b–d) or the brain stem (Fig. 3e). These data
show an identical pattern to those seen when we fed mice a HFD
supplemented with FC inulin9. We went on to investigate specific
changes in hypothalamic neuropeptide expression following i.p.
acetate administration. There was a four-fold rise in the
expression of the melanocortin precursor pro-opiomelanocortin
(POMC) and a potent suppression of agouti-related peptide
(AgRP) expression 30min after acetate administration (Fig. 3f).
At 60min, this suppression of AgRP remained. This disparate
change in the expression patterns of anorectic and orexigenic
neuropeptides favour a reduction in appetite and body weight,
and have been previously reported by others feeding rodents
FC-rich diets17.
Acetate reduces hypothalamic AMPK catalytic activity. Mam-
malian neuronal tissue is thought to rapidly convert acetate to
acetyl-CoA, which then enters the Krebs cycle13. Accumulating
evidence suggests that hypothalamic AMP-activated protein
kinase (AMPK) has an important role in energy and nutrient
sensing18. Phosphorylation of threonine 172 (T172) within the
alpha subunit of AMPK directly activates the kinase, which in
turn phosphorylates and inactivates acetyl-CoA carboxylase
(ACC), leading to decreased levels of malonyl-CoA. Studies
have shown that increased hypothalamic malonyl-CoA
concentrations are associated with an increase in the expression
of POMC19 and suppression of Neuropeptide Y (NPY) and AgRP
with a subsequent reduction in rodent food intake. Thus, we
hypothesized that acetate administration may mediate the
changes in appetite we had observed and also more specifically
changes in POMC and AgRP expression. We measured the
phosphorylation of key residues of AMPK (T172) and ACC (S79)
in mouse hypothalamic lysates following i.p. acetate injection as a
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Figure 1 | FCs reduce food intake and increase faecal SCFA concentrations. (a) Body weight gain and (b) average weekly food intake of mice fed
with either a HFD supplemented with the highly fermentable fibre inulin (HF-I) or a relatively non-fermentable fibre cellulose (HF-C). Body weight gain and
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depicts a fasted mouse following i.v. infusion. Image shows uptake in the brain, liver and heart. (e–g) Brain, liver and heart uptake of i.v. and colon
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U-test, were observed between i.v. administrations in the fed or fasted state, but there is a slower increase when the 11C-acetate was colonically
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surrogate of their activities. We found a significant reduction in
levels of pT172 of AMPK and pS79 of ACC (Fig. 3g–i), suggesting
that acute acetate administration inactivated AMPK, thereby
leading to increased ACC activity. Increased ACC activity has
been shown to elevate malonyl-CoA that can stimulate expression
of POMC and cocaine- and amphetamine-regulated transcript
and decrease NPY and AgRP leading to a reduction in food
intake19. This therefore suggests that the anorectic effects of
acetate administration are mediated through a change in
hypothalamic ACC and AMPK activities and downstream
changes in neuropeptide expression. A schematic illustration of
this relationship is shown in Fig. 3j.
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Figure 2 | Acetate administration reduces food intake. (a) Serum acetate concentrations of mice administered with 500mg kg 1 i.p. acetate or saline
(n¼ 12). (b) Acute food intake data showing food intake in mice following the acute i.p. administration of acetate (500mg kg 1) or saline. Food
Intake significantly reduced at 0–1 and 0–2 h; ***Po0.001, **Po0.01 (n¼ 21–22 per group). (c) The effect of 2.5mmol of sodium acetate administered into
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13C acetate preferentially accumulates in the hypothalamus.
Given the aforementioned changes in neuronal activation and
neuropeptides expression, we sought to determine the hypotha-
lamic metabolism of acetate using 13C high-resolution magic-
angle-spinning (HR-MAS). Figure 4 summarizes the results on
hypothalamic metabolism of i.p. (2-13C) acetate or 13C2 acetate
derived from colonic fermentation of (U-13C) inulin administered
by gavage. 1H-decoupled 13C HR-MAS spectra of cerebral
biopsies provide information on the operation of the tricarboxylic
acid cycle (TCA) and the transcellular glutamate–glutamine and
g-amino butyric acid (GABA) cycles20,21. Here we implemented
the 13C HR-MAS approach to investigate the metabolism of
labelled [2-13C] acetate or 13C2 acetate in the hypothalamus of
fasted mice as well as in biopsies from the ‘remaining brain’
obtained for comparison. To this end, brain metabolism was
arrested with focused microwaves immediately after (0min) or
15 and 30min later, following the i.p. administration of (2-13C)
acetate or 180min after intragastric (U-13C) inulin
administrations, and a biopsy of the hypothalamus surgically
separated from the remaining brain, investigating 13C labelling in
both samples. Figure 4a depicts 13C HR-MAS spectra from a
representative mouse hypothalamus 15min after [2-13C] acetate
administration, revealing extensive 13C incorporation and
indicating the most relevant resonances observed. The inset
shows a representative 13C HR-MAS spectrum (28–38 p.p.m.),
obtained from the hypothalamus of a mouse, 180min after (U-
13C) inulin administration by gavage. The presence of clearly
resolved doublets in hypothalamic glutamate C4 (1J45¼ 51Hz),
glutamine C4 (1J45¼ 49Hz) and GABA C2 (1J12¼ 51Hz)
demonstrates that 13C2 acetate units produced by colonic
fermentation of (U-13C) inulin have been incorporated into
hypothalamic metabolism. Figure 4b shows the time course of
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13C incorporation from these substrates in acetate C2, glutamate
and glutamine C4, GABA C2 and lactate C3 carbons in the
hypothalamus biopsy (light grey), as well as in the remaining
brain biopsy (dark grey). The 13C HR-MAS resonance of acetate
C2 increased significantly with time reaching higher intensity in
the hypothalamus than in the remaining brain, revealing a
heterogeneous distribution of cerebral acetate levels with a
preferential accumulation of this substrate in the hypothalamus.
In addition, the 13C resonances of Glu C4, Gln C4 and GABA C2
also increased significantly with time both in intra- and extra-
hypothalamic structures, supporting substantial metabolism of
accumulated 13C acetate in the cerebral TCA cycle and neuroglial
glutamate–glutamine or GABA transcellular cycles (Fig. 4c). To
investigate whether the concentrations of acetate derived from
fermentation in the colon would be sufficiently high to
unambiguously label these metabolites in the hypothalamus
(and trigger the anorectic responses described), we used (U-13C)
inulin. Interestingly, 13C accumulation in these metabolites from
intragastric (U-13C) inulin was often higher than from i.p. (2-13C)
acetate, revealing an efficient fermentation of the inulin in the
mouse colon at a level that directly influences hypothalamic
metabolism.
13C2 acetate from U-13C inulin labelled faster Glu C4, Gln C4
and GABA C2 in the hypothalamus than in the rest of the brain.
In fact, no detectable 13C incorporations in GABA C2 or Gln C4
could be found in the remaining brain biopsies, even when 13C
incorporation into the common Glu C4 precursor was similar in
both regions. We believe that this is the result of the preferential
incorporation of 13C2 acetate and its metabolism in the
hypothalamus as compared with the remaining brain, suggesting
that Gln C4 and GABA C2 labelling in non-hypothalamic
structures would occur at later times.
Notably, 13C GABA and 13C lactate remained at a similar level
until 30min when both 13C GABA and 13C lactate were higher in
the hypothalamus than in the remaining brain biopsies, indicating
a relative increase in gabaergic neurotransmission and oxidative
13C lactate production from the pyruvate recycling pathway in
the mouse hypothalamus under appetite stimulation22.
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after [U-13C] inulin administration (100mg) by gavage. (b) Increases in 13C incorporation into the acetate C2, GABA C2, Glu C4, Gln C4 and Lac
C3 carbons (meanþ s.d.) in the hypothalamus and remaining brain biopsies, following 0, 15, 30min i.p. [2-13C] acetate (n¼ 18) or 180min intragastric
[U-13C] inulin administrations *Po0.05, **Po0.01, ***Po0.001 (n¼4). (c) Summary of the effects of [2-13C] acetate or [U-13C] inulin administrations in
hypothalamic metabolism. Extracellular [2-13C] or 13C2 acetate derived from plasma or cerebrospinal fluid are transported primarily to the astrocytes,
where they are metabolized oxidatively in the TCA cycle, labelling astrocytic glutamate C4 and glutamine C4 that exchange with the corresponding
neuronal pools through the glutamate–glutamine cycle, labelling GABA only in gabaergic neurons. (2-13C) or 13C2 acetate are also oxidatively recycled in
the neuronal cycle, originating the Lac C3 resonance. The glutamate–glutamine and GABA cycles support glutamatergic and gabaergic neurotransmissions,
the two fundamental synaptic events triggering increased Ca2þ uptake and competitive Mn2þ uptake (MEMRI) that determine the appetite impulse.
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In order to evaluate the contribution of potential variations in
total metabolite content to the 13C incorporation profiles, we
acquired 1H HR-MAS spectra for the same biopsies we used for
the 13C HR-MAS acquisitions, as the resonances detected by 1H
HR-MAS are known to reveal the total metabolite content.
Figure 5a, shows a representative 1H HR-MAS spectrum from a
biopsy obtained from the hypothalamus, 180min after (U-13C)
inulin administration (black trace), with some of the most
relevant metabolite resonances highlighted and the corresponding
LCModel fitting superimposed (red trace). We calculated the
metabolite ratios for acetate, GABA, glutamate, glutamine and
lactate using the total myo-inositol or the total creatine (Crþ
PCr) resonances as internal references. Our results revealed that
the significantly higher 13C incorporations in hypothalamic
acetate C2, GABA C2, glutamate and glutamine C4 and Lac C3
are primarily derived from the 13C-labelled substrates adminis-
tered rather than from relative changes in total metabolite content
(Fig. 5b–f). Notably, similar levels of total glutamine and
total GABA were found in the hypothalamus and remaining
brain biopsies 180min after (U-13C) inulin administration
(Fig. 5c,d). confirming that the higher 13C incorporations
detected in hypothalamic Gln C4 and GABA C2, are not derived
from relative changes in the total metabolite levels between these
two regions. Similar conclusions were obtained when using the
total creatine (Crþ PCr) resonance as internal reference for the
total metabolite content. This normalization allowed, however,
for the comparison between the myo-inositol content in the
hypothalamus and the remaining brain. No significant differences
in Ino/(Crþ PCr) ratios were found between both regions, 15 or
30min after (2-13C) acetate, or 180min after (U-13C) inulin
administrations. These results suggest that previously reported
differences in myo-inositol content between the untreated mouse
hypothalamus and hipoccampus23 do not contribute appreciably
to the present comparisons between the hypothalamus and
remaining brain biopsies after (2-13C) acetate or (U-13C) inulin
administrations.
Summarizing, we conclude then that the neuronal activation in
the ARC observed in Fig. 3b using MEMRI occurs because of a
relative increase in acetate and glutamatergic or gabaergic
neurotransmissions in the hypothalamus that would result
in divalent ion uptake, in this case Mn2þ , and therefore an
increase in MEMRI signal intensity as shown in our summary
schematic (Fig. 4c).
Discussion
In this paper, we provide a novel insight into the mechanism
behind the well-established observation that animals fed a HFD
supplemented with FC have decreased energy intake and weight
gain24,25. Most of the work in this area investigating the
mechanism underlying these observations has previously
focused on the potential effect of FC to promote the release of
the anorectic gut hormones PYY and GLP-1 (ref. 6). However,
increased concentrations of these hormones have been difficult to
reproduce in humans26. In previous studies from our group, we
have observed that decreased food intake and diminished body
weight can occur independently of change in gut hormones in
mice9,24. We also observed an increase in MEMRI signal in the
hypothalamic ARC, with no associated increase in signal intensity
in the brain stem, the opposite to that observed following
administration of the anorectic gut hormones GLP-1 and PYY27.
Here we have demonstrated that the decrease in body weight
observed in FC supplementation studies appears to be mediated,
at least in part, by the SCFA acetate. Acute i.p. injection of acetate
decreased energy intake over 2 h without effecting behaviour and
occurred independently of changes in the peripheral
concentrations of GLP-1 and PYY. It is of interest that
encapsulation of acetate into liposomes, which specifically
allows for peripheral delivery, abolishes the anorectic effect of
acetate in mice, whereas i.c.v. administration of acetate in rats,
although still anorectic, shows a milder and more delayed
suppression of food intake. The lack of brain-stem-induced
changes in signal intensity following i.p. acetate do not suggest a
vagally mediated effect of acetate, and thus the difference in
potency may be because of species variation. We also demonstrate
that appetite changes are unlikely to be because of change in the
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Figure 5 | Relative changes in total metabolite content in the hypothalamus and remaining brain biopsies after (2-13C) acetate or (U-13C) inulin
administrations. (a) 1HR-MAS spectrum from a representative biopsy from the hypothalamus (black) and superimposed LCModel fitting (red).
(b–f) Relative 1H HR-MAS ratios Ac/Ino, GABA/Ino, Glu/Ino, Gln/Ino and Lac/Ino at increasing times after (2-13C) acetate or (U-13C) inulin admini-
strations. Lac, lactate; Ac, acetate;, Glu, glutamate; Gln, glutamine; GABA, g-amino butyric acid; Crþ PCr, creatineþ phosphocreatine; Ino, myo-inositol;
n.r, not resolved; CRLB, Cranmer–Rao Lower Bound o20%. Bar graphs represent the mean and standard deviation. Statistical significance was evaluated
using two-tailed unpaired Student t-test. ‘‘Remaining brain’’ accounts for cerebral extra-hypothalamic tissue. *Po0.05, **Po0.01.
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availability of glucose to the hypothalamus, as acetate did not
affect circulating glucose concentrations. We have also shown
that acetate administered through both i.v. and colonic routes is
taken up by the brain and for the first time that acetate derived
from fermentation of carbohydrate in the colon is taken up by the
hypothalamus in greater amounts than other brain tissue.
MEMRI signal intensity patterning following acetate infusion
also directly reflects that of animals fed with FC9. Furthermore,
we have shown that peripheral acetate administration leads to
increased POMC and reduced AgRP expression in the
hypothalamus, suggesting that acetate has a direct effect on the
hypothalamic control of appetite. Similar observations have been
made when animals are fed with FC17.
Changes in the phosphorylation of key residues of AMPK and
ACC in mouse hypothalamic lysates following peripheral acetate
administration also provides evidence of a potential mechanism
through which the changes in neuropeptide expression might
occur. Given that acetate is taken up by the hypothalamus, where it
is preferentially metabolized by astrocytes because of the higher
activity of their monocarboxylate transporters compared with
neurons28,29, a non-neuronal mechanism may also be implicated in
the observed increase in ARC activation. Using 13C HR-MAS in
whole hypothalamic tissue, we were able to demonstrate that 13C
acetate from both i.p. injections and derived from colonic
fermentation incorporates into the glutamate–glutamine trans-
cellular cycle, increasing lactate and GABA labelling, thus
supporting hypothalamic glutamatergic or gabaergic neurotrans-
missions. The same model has been proposed to occur in acetate
metabolism following alcohol ingestion30. The operation of the
glutamine cycle involves imperative signalling through ionotropic
and metabotropic postsynaptic glutamate receptors, resulting in
increased intracellular Ca2þ accumulation22 and a concomitant
MEMRI effect31 (Fig. 4c). It has recently been demonstrated that
leptin modulates glutamate transporter expression in hypothalamic
astrocytes with an associated increase in POMC neuron
excitability32. A similar mechanism could take place following
acetate administration, potentially explaining the increase in
MEMRI signal observed in ARC of animals supplemented with
FC or given acetate alone. We hypothesize that the increase in
hypothalamic 13C acetate over time, as compared with rest of the
brain, results in increased hypothalamic gabaergic neuro-
transmission and oxidative lactate production from the pyruvate
recycling pathway22. Increased oxidative metabolism results in
increased ATP production, decreasing the AMP:ATP ratio, and
thereby decreasing AMPK activity and consequently reducing the
inhibition of ACC. This produces an increase in malonyl-CoA,
stimulates POMC neurons and predominantly gabaergic
neurotransmission, thus decreasing the appetite impulse33.
Dietary intakes of fibre in excess of 100 g per day consumed by
Palaeolithic man and in some hunter gather tribes4 suggest the
human colon is adapted to large intakes of fermentable material
that would lead to high-peripheral circulating acetate34. The fall
in fibre intakes or, more specifically, a decline in the intake of
carbohydrates that can be readily fermented in the colon are one
such factor that seems to be an inverse correlate of obesity
prevalence. Although studies have suggested that the inclusion of
highly FC diets may be beneficial in terms of regulation of both
appetite and body weight, in free-living individuals, compliance
to such eating regimens is often low due to gastrointestinal side
effects or unpalatability of FC-rich foodstuffs. The work
highlighted within the paper suggests that the SCFA acetate
may at least in part mediate some of the obesity-protective effects
of FC-rich diets directly in the central nervous system, thus
suggesting that acetate may be useful as a potential anti-obesity
therapeutic. This hypothesis does not rule out that there are other
non-specific effects.
In conclusion, here we provide novel insight into a mechanism
through which FC may mediate appetite suppression. By
exploring the role of the SCFA acetate, a product of fermentation
of carbohydrate in the colon, our evidence suggests that acetate
derived from the colon induces an anorectic signal in the
hypothalamic ARC by supporting the glutamate–glutamine
transcellular cycle and leading to an increase in lactate and
GABA production. These data demonstrate a previously
unexplored central mechanism through which the fermentation
products of FC and dietary fibre may aid in the control of body
weight beyond that of energy dilution and gut hormone release.
Moreover, it opens up important new possibilities for weight
management as the supply of fermentable substrate to the colon
(and therefore acetate production) can be modified.
Methods
Animals and treatments. Animal experiments were performed at Imperial
College London except for high resolution magic angle spinning (HMRS) experi-
ments which were performed at Instituto de Investigaciones Biome´dicas ‘Alberto
Sols’ (IIB). Experiments conducted at Imperial College London were approved by
Imperial College London, and all animal procedures were performed in accordance
with the UK Animals Scientific Procedures Act (1986). IIB experiments were
approved by the ethical committee of the Instituto de Investigaciones Biomedicas
‘Alberto Sols’ (and met the guidelines of the national (R.D. 53/2013) and the
European Community (2010/62/UE) for care and management of experimental
animals. Unless otherwise stated, all experiments were performed in C57BL/6 male
mice (6–8 weeks old, Charles River, Margate, UK) that were single-housed under
controlled temperature (21–23 oC) and light conditions (12 h light–dark cycle;
lights on at 07:00 hours).
The effect of HF-I versus HF-C on body weight and energy intake. Mice were
randomized and assigned to two different groups (n¼ 12): HFD with cellulose as a
control (HF-C), HFDþ oligofructose-enriched inulin (Synergy) (HF-I). Synergy is
a fructan-based preparation containing both long- and short-chain fructo-oligo-
saccharides. Synergy was mixed with the HFD individually in the ratio of 1:9. The
two diets were isocaloric, each contained the same total energy of 4.6 kcal g 1, with
41.8% energy from fat. The diets were made isocaloric by the addition of cellulose.
Nutritional composition of the diet is shown in Table 1. The diets were fed ad
libitum for 8 weeks to respective groups of animals. Body weights and food intake
were measured three times per week.
Determination of acetate concentrations in serum and faeces. SCFAs were
determined by gas chromatography in the colonic contents and serum of mice that
where freshly culled. The method used was adapted from Richardson et al.35
Briefly, caecal contents were weighed (20–220 mg) and combined with 550 ml of
PBS. Samples were vortex mixed for 1min, centrifuged at 3,000 g for 10min and
the supernatant was collected. To 500 ml supernatant, 25ml of internal standard
and 2-ethylbutyric acid was added to give a final concentration of 5mmol l 1.
Acids were extracted by the addition of 250 ml concentrated hydrochloric acid
and 1ml diethyl ether followed by vortex mixing for 1min. Samples were centri-
Table 1 | Nutritional content of the HFD-C and HFD-I diets.
Diets HF-C HF-I
Ingredients g kg 1 g kg 1
Energy (kcal g 1) 4.6 4.6
Casein 195.0 195.0
DL-Methionine 3.0 3.0
Sucrose 342.96 342.96
Corn starch 75.0 75.0
Maltodextrin 75.0 75.0
Anhydrous milk fat 210.0 210.0
Cellulose 110.0 50.0
Mineral mix (AIN-76) 35.0 35.0
Calcium carbonate 4.0 4.0
Vitamin mix (Teklad) 10.0 10.0
Ethoxyquin, antioxidant 0.04 0.04
Inulin 0.0 100.0
b-glucan 0.0 0.0
HF-C, high-fat diet with cellulose as a control; HF-I, HFDþ oligofructose-enriched inulin.
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fuged for 10min at 3,000 g and the ether layer was removed and transferred to a
separate capped vial. N-methyl-N-t-butyldimethylsilyltrifluoroacetamide
(MTBSTFA; Sigma) was added (100 ml) before heating at 80 C for 20min.
Gas chromatography was performed on a Hewlett Packard 5890 Series II
instrument equipped with a flame ionization detector, split/splitless injector and a
10-m, 0.18mm ID and 0.20 mm df Rtx-1 (Crossbond 100% dimethyl polysiloxane,
Thames Restek UK, Ltd) capillary column. Injector and detector temperatures were
275 oC with the column temperature programmed from 63 C for 3min to 190 oC
at 10 C per min. Helium served as the carrier gas (head pressure 135 kPa) and
injections (1 ml) were made in the split mode (50:1 split). Peak areas were recorded
and all subsequent data manipulation was completed using ChemStation Software
(Agilent Technologies, USA). External standards for acetate, propionate,
n-butyrate, iso-butyrate, n-valerate and caproate were prepared at concentrations
of 25, 12.5, 6.25, 1.25 and 0.625mM and ethyl butyric acid was used as the internal
standard at a concentration of 100mM. Reported values were normalized
according to the weight of original sample used.
Serum SCFA measurement. A 100–500-ml aliquot of serum was filtered through a
30-kDa micropartition system (Vivaspin RC VS02H22 filters, Sartorius Inc.,
Mississauga, ON, Canada) by centrifugation at 14,000 g at 4 C for 90min. An
internal standard solution (25 ml) consisting of 100mM ethylbutyrate and 100mM
formic acid was added to 225 ml of the protein-free filtrate supernatant in a 2-ml
Hichrom vial (Agilent Technologies, South Queensferry, UK). To measure SCFA,
1 ml of each sample was injected into a 5,890 Series II GC system (HP, Crawley,
UK) fitted with a NukolTM Capilllary Column (30m 0.53mm 1.0 mm,
SUPELCOTM Analytical, UK) and flame ionization detector. The carrier gas,
helium, was delivered at a flow rate of 14mlmin 1. The head pressure was set at
10 p.s.i. with split injection. Run conditions were: initial temperature 60 C, 1min;
þ 20 Cmin 1 to 145 C; þ 4 Cmin 1 to 200 C, hold 25min. Peaks were
integrated using Agilent ChemStation software (Agilent Technologies, Oxford, UK)
and SCFA content quantified by single-point internal standard method. Peak
identity and internal response factors were determined using a 1-mM calibration
cocktail including acetate, propionate and butyrate.
PET-CT analysis of acetate biodistribution. Mice were fasted overnight. Animals
received 11C-acetate (B20MBq) at the beginning of PET scan either through i.v.
tail vein (n¼ 3) or colonically by using tubing placed 1 cm into the rectum (n¼ 4).
At the time of the scan, animals were anaesthetized with a 2–2% isofluorane–
oxygen mix. After the animals were placed in the micro PET/CT scanner (PET/CT
(Siemens), a CT scan without contrast was performed, followed by the PET scan
and lastly followed by a CT scan where contrast Ultravist 370 (Bayer, AG,
Germany) was infused.
During the scan, animals were maintained at 1–1% isofluorane–oxygen mix and
body temperature of 37 C. The CT had an X-ray source of 80 kVp and 500 mA
with exposure time 200ms and isotropic resolution of 103 mm. The scan consisted
of three bed positions with a 20% overlap. The CT scan was used for anatomical
data and attenuation correction purposes. The PET system consisted of 64 lutetium
oxyothosilicate based detectors blocks arranged in four contiguous rings, with a
crystal ring diameter of 16.1 cm and an axial extent of 12.7 cm. Each detector block
was composed of a 20 20 array of lutetium oxyothosilicate crystals coupled to a
position sensitive photomultiplier tube via a light guide. Each crystal was 10mm
long and had a cross-sectional area of 1.51 1.51mm. The crystal pitch was
1.59mm in both axial and transverse directions. Inveon Research Workplace
version 3 (Siemens) was used for data analysis. Images with matrix size 12 128,
pixel size 0.776mm2 and slice thickness 0.796mm were reconstructed from the
two-dimensional sinogram by two-dimensional-filtered backprojection using a
ramp filter with a nyquist frequency of 0.5. Dynamic framing was used in
reconstruction with 20 3 s frames, 8 30 s frames, 5 60 s frames and 10 300 s
frames. Attenuation correction was also used to correct the image. Reconstructed
PET images were then registered onto the CT images. PET signals on the desired
region of interest were obtained over the scan period (1 h). Percentage injected dose
(% ID per g) was calculated by using the following Equations (1) and (2), where;
l¼ 0.693/T1/2, T1/2 is the half-life of the radionuclide, It is activity at a given time
where I0 is the starting activity and t is the time passed, CPET is the contrast of the
image and ID is the activity of the injected acetate.
% ID=g¼CPET=ID100 ð1Þ
It¼I0e lt ð2Þ
Effect of i.p. acetate on energy intake. Mice were fasted overnight before
receiving either 500mg kg 1 sodium acetate dissolved in 0.9% saline (n¼ 22) or
vehicle control (0.9% saline; n¼ 21) pH 7.0, This dosage of acetate was similar to
that used to suppress lipolysis in previous studies and was shown to be well
tolerated14. Food intake was measured 1, 2, and 4 h post injection.
Effect of i.c.v. acetate on energy intake. Male Wistar rats 190–240 g (specific
pathogen free; Charles River) were placed in a stereotaxic frame (David Kopf
Instruments) under 0.5-2.5% isoflurane anaesthesia. A hole was drilled using a
stereotactically mounted electric drill using coordinates calculated from the Rat Brain
Atlas as described previously36, according to the coordinates of Paxinos and
Watson37 (0.8mm posterior to the Bregma in the midline and 6.5mm below the
surface of the skull). A permanent 22-gauge stainless steel cannula (Plastics One Inc.,
Roanoke, Virginia, USA) projecting to the third cerebral ventricle was implanted.
Dental cement was used to hold the cannula in position anchored by three stainless
steel screws inserted into the skull. The skin was approximated using nylon sutures.
After a 7 day recovery period, animals were handled daily and acclimatized to the
injection procedure. To ensure that cannulae were correctly positioned, rats received
i.c.v. 150 ng angiotensin II in a 5-ml volume via a 28-gauge stainless steel injector
placed into and projecting 1mm below the tip of the cannula. Rats were observed for
a prompt drinking response. A total volume of 5ml was injected over 1min to
conscious, freely moving rats. For feeding studies, rats (n¼ 15) were fasted overnight
and then injected between 09:00 and 10:00 hours with sodium acetate (2.5mmol) or
an equivalent osmotic sodium chloride control (5ml) and returned to their home
cage. Food intake was measured at 1, 2 and 4 h post injection. After a 72-h washout
period, rats received either the acetate or sodium chloride in a cross-over manner
and food intake measured as previously described.
Effect of liposome encapsulate acetate on food intake. Nanoparticle design was
based upon our previous studies where PEGylated liposomes were formulated for
labelling and visualization of cells38, or specifically designed for preferential uptake in
xenograft tumours15. Liposomes were prepared by the thin-film hydration method39.
Liposomes were prepared with either acetate (1 M, pH 2.3) to form liposome-
encapsulated acetate (LITA) nanoparticles or HEPES for use as a control. Particle size
was determined using a Malvern Zetasizer (Malvern Instruments, UK). Quantification
of acetate encapsulated within LITA nanoparticles was determined using 1H nuclear
magnetic resonance (NMR) spectroscopy. LITA formulation (200ml) was scanned
with addition of albumin that binds to acetate in free solution reducing the NMR
signal for the compound40. A liposome-free control solution containing an equivalent
concentration of acetate (4mM) was also scanned with and without the addition of
albumin (2 g). LITA solution was scanned following the addition of lactate (5.2mg
sodium lactate) to act as a quantitative control. Spectra were obtained using a Bruker
DRX 11.74T NMR spectrometer. Spectra were analysed using MestRe-C NMR
spectroscopy software (Santiago de Compostela, Spain).
To assess short-term biodistribution, a liposome formulation containing an
additional 0.1% of a rhodamine–lipid complex (DOPE-Rhodamine: 1,2-dioleoyl-sn-
glycero-3-phosphoethanolamine-N-(lissamine rhodamine B sulfonyl) was used to
determine biodistibution through ex vivo histological analysis. Samples were
collected 4 h post i.p. injection (n¼ 4). No significant accumulation of liposome was
observed in the brain of the treated mice despite being present in the liver and heart.
The effect of acetate on behaviour. Mice were fasted overnight before receiving
either a single i.p. injection of saline, 500mg kg 1 acetate or 2.5M LiCl as a
positive control for aversive behaviour41 (n¼ 8 per group). The behavioural
patterns of each mouse were observed for 15 s every 5min from the time of
injection until 1 h post injection. Behaviours was classified using a modified version
of a previously published protocol42. Briefly, behaviours was classified into 10
different categories: feeding, drinking, locomotion (including rearing and
climbing), bed making, burrowing, grooming, still, sleeping, head down (animal in
abnormal body posture: back hunched, eyes shut or half-shut and pilo erect—
indicative of impaired health status) and tremors.
Acetate tolerance test. Glucose levels were determined from blood taken from
mouse tails using a Glucometer Elite glucometer (Bayer Corp.). Experiments were
performed on ad libitum fed mice at 14:00 h as previously described for insulin
tolerance tests18 but instead of insulin, animals were injected i.p. with either
500mg kg 1 sodium acetate or saline control (n¼ 9–10). Blood glucose values
were then determined at the times indicated. Results were expressed as fold change
of initial blood glucose concentration before injections.
Plasma PYYand GLP-1 hormone analysis. All samples were assayed in duplicate
and in a single assay to eliminate inter assay variation. Plasma PYY and GLP-1
were assessed using an established in-house radioimmunoassay as described
previously43,44.
Hypothalamic quantitative PCR. This was carried out using the methods
described by Bewick et al.45 Quantitative reverse transcriptase PCR (RT-qPCR) was
used to study the expression of the different target genes. Total RNA was extracted
from the whole hypothalami using TRIZOL (Invitrogen) according to the
manufacturer’s protocol. All samples were treated by DNaseI (Invitrogen) before
the reverse transcription. First-strand cDNAs were prepared using 1 mg RNA and
SuperScriptII Reverse Transcriptase (Invitrogen) in the presence of random
hexamer and oligo(dT) primers (Promega, Charbonnie`res-les-Bains, France). The
qPCRs were performed using the Light Cycler Fast Start DNA Master SyBR Green
I kit (Roche, Meylan, France) in the presence of specific primer pairs that were
selected to amplify small fragments (100–200 bp). PCR products were checked for
NATURE COMMUNICATIONS | DOI: 10.1038/ncomms4611 ARTICLE
NATURE COMMUNICATIONS | 5:3611 | DOI: 10.1038/ncomms4611 | www.nature.com/naturecommunications 9
& 2014 Macmillan Publishers Limited. All rights reserved.
specificity by measuring their melting temperature. Samples (in duplicate) were
quantified by comparison with a standard curve obtained by dilutions of purified-
specific cDNAs.
Measurements of AGRP and POMC mRNA expression. RNA was extracted
from dissected hypothalamus using Absolutely RNA microprep kit from Stratagene
(La Jolla, CA, USA). The gene transcription for AgRP and POMC in the ARC of the
hypothalamus was determined using real-time RT-PCR, and results were expressed
as a ratio to the expression of the constitutive gene cyclophilin. The sequences of
TaqMan probes and primers for cyclophilin (GenBank accession no. M15933) were:
forward primer 50-CCCACCGTGTTCTTCGACAT; reverse primer 50-TGCAAAC
AGCTCGAAGCAGA-30 ; and probe 50-CAAGGGCTCGCCATCAGCCG-30 . For
AGRP, they were: forward primer 50-TTGGCAGAGGTGCTAGATCCA-30 ; reverse
primer 50-AGGACTCGTGCAGCCTTACAC-30; and probe 50-CGAGTCTCGTT
CTCCGCGTCGC-30 . The probe and primers for POMC (assay identification no.
Rn00595020_ml) were purchased from Applied Biosystems.
Manganese-enhanced MRI. MEMRI was performed using a 9.4-Tesla Varian
INOVA imaging system (Varian Inc., USA) as described previously46. A fast spin-
echo multi-slice sequence was applied with the following parameters: TR¼ 600ms,
TE¼ 10ms, matrix size¼ 256 192, FOV¼ 25 25mm and average¼ 1
acquiring 46 0.4mm thick slices. An array of 66 acquisitions was set up so that
the 46 slices were acquired 66 times throughout the infusion. Normalized
percentage enhancement in signal intensity was calculated for the ARC, VMH,
PVN, periventricular nucleus (PE) and the nucleus of tractus solitarius27,43.
Hypothalamic measurement of AMP kinase. Animals were killed by decapita-
tion, brains were immediately dissected and the hypothalamus was removed and
snap-frozen in liquid nitrogen. Frozen tissues (B100mg) were homogenized in
0.4ml of ice-cold 50mm HEPES, pH 7.4, 50mm sodium fluoride, 5mm sodium
pyrophosphate, 250mm sucrose, 1mm EDTA, 1mm dithiothreitol, 1mm benza-
midine, 1mm trypsin inhibitor, 0.1% (w/v) phenylmethylsulfonyl fluoride using an
UltraTurax homogenizer (3 30-s bursts). Insoluble material was removed by
centrifugation and the resulting supernatant was used for immunoprecipitation of
AMPK and western blot analysis.
Immunoblotting and antibodies. Samples were boiled in electrophoresis sample
buffer and resolved on polyacrylamide gels. Proteins were transferred into PVDF
membrane (Immobilon-FL, Millipore) and blocked with PBS containing 5%
skimmed milk powder for 1 h. Antibodies were diluted in 5ml high salt Tween
buffer (20mM Tris, pH 7.4, 500mM NaCl and 0.5% Tween (v/v)), and incubated
with the membrane. Primary antibodies used for immunoblotting are as follows:
anti-AMPK-b1/2 (in-house) (dilutions 1:3,000–1:10,000 for blotting), anti-phos-
pho-ACC (S79) (Cell Signalling, cat. no. 3661), anti-phospho-AMPK (PT172) (Cell
Signalling, cat. no. 2535) anti-b-actin (Sigma, cat. no. A5316).
Primary antibodies were detected using fluorescently linked secondary
antibodies (Alexa Fluor, Invitrogen, goat anti rabbit: A21109 and goat anti mouse:
A21058). These were visualized using an Odyssey infrared imager (Li-Cor
Biosciences). Quantification of results was performed using Odyssey software and
expressed as a ratio of the signal obtained with the phospho-specific antibody
relative to the appropriate total antibody. Full-length images of cut immunoblots
are shown in Supplementary Fig. 1.
The effect of acetate on hypothalamic metabolism. [2-13C] acetate
(500mg kg 1) or [U-13C] inulin (100mg) were administrated to 8–10-week-old
C57BL/6J male mice (Charles River, Spain) after an overnight fasting (16 h) either
with i.p. (n¼ 18) or by gavage (n¼ 4), respectively. All mice were anaesthetized
with 4% isoflurane (3 l per min, 99% oxygen), and cerebral metabolism was
arrested within 1.5 s using a high-power (5 kW) microwave fixation system (TMW-
6402C, Muromachi Kikai Co. Ltd, Tokyo, Japan) immediately (0min), 15 and
30min after acetate, or 180min after inulin, administrations. Fixed brains were
dissected and hypothalamus and remaining brain biopsies were obtained and
maintained frozen ( 80 C) until HR-MAS analyses. 13C (125,03MHz) and 1H
HR-MAS (500,13MHz) spectra were acquired at 11.7 T (4 C, 4,000Hz rotation)
with a Bruker AVANCE wide bore spectrometer equipped with a MAS accessory
(Bruker Biospin, Rheinstetten, Germany). 1H-decoupled 13C HR-MAS spectra
were acquired using a pulse-acquire sequence, with WALTZ-16 1H decoupling
applied during the acquisition and relaxation delay periods. Conditions were p/4
pulses, 8,192 or 16,384 scans (for [2-13C] acetate or [U-13C] inulin measurements,
respectively), 64 k data points, 5 s recycle delay. The 13C spectra were processed
with Mestrelab (http://mestrelab.com/). Chemical shifts of the 13C resonances were
referred to the acetate C2 resonance (24.5 p.p.m.), and the 13C incorporation was
normalized to the myo-inositol C1þC3 resonance (73.2 p.p.m.), which provides a
useful internal reference from which all 13C resonances can be normalized inde-
pendently of the amount of tissue20,47, introducing appropriate corrections for
nuclear Overhausser enhancement and saturation.
1H HR-MAS spectra from the same biopsies used for 13C HR-MAS acquisitions
were acquired using the Carr-Purcell-Meiboom-Gil sequence. Acquisition
parameters were 5 s water pre-saturation, echo time¼ 144ms, t¼ 1ms, n¼ 100,
10 kHz spectral width, 32 k data points and 256 scans. Metabolite concentrations
were evaluated using a modified version of the LCModel processing software
(Linear Combination of Model Spectra, http://s-provencher.com/pages/schtm)48.
Statistical tests were performed using two-tailed unpaired Student’s t-test
between values in the different time points or areas. Observations that fell below
the Q1-1.5 IQR (interquartile range) or above the Q3þ 1.5 IQR range (with Q1
and Q3 representing the upper and lower quartiles values and IQR, the difference
between Q3 and Q1) were considered outliers and were not taken into account for
statistical evaluations.
Data analysis. Analyses were performed using Graph Pad Prism (GraphPad
Software, San Diego, CA, USA) or Stata (StataCorp LP, College Station, TX, USA).
All data was tested for normality using Shapiro–Wilk test. Non-normally dis-
tributed data was log transformed to normalize the distribution. Comparison
between groups was carried out by two-sided unpaired Student’s t-test for two
groups and one-way analysis of variance (ANOVA) with post hoc Tukey or Bon-
ferroni correction if there were more than two groups. I.c.v. cross-over acetate
injection studies were compared using a two-sided paired Student’s t-test. Given
the cumulative nature of both MEMRI and PET signal intensity data, differences in
signal intensity profile between the regions of interest in all experimental groups
were analysed using GEE and the Mann–Whitney U-test with commercial statis-
tical software (Stata, version 9.1; StataCorp), which compare profiles for the
entirety scan. All results and graphs are expressed as means±s.e.m. Results were
considered statistically significant when Po0.05, with the significance level indi-
cated as *Po0.05, **Po0.01 and ***Po0.001
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